Genclis SAS : Confirms Potential of its Severidia(R) Test

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Genclis SAS : Confirms Potential of its Severidia(R) Test on 47 TNBC patients
  • 100% of patients classified with Severidia® in the "good outcome" subgroup were alive after 2,500 days
  • Improved p value (p < 10 -5 )

NANCY, France, Nov. 25, 2014 (GLOBE NEWSWIRE) -- Genclis, a molecular diagnostic company in the fields of allergy and cancer, today presents additional clinical data for its molecular diagnostic test Severidia ® in non-metastatic triple-negative breast cancer patients in the context of the 4 th Munich Biomarker Conference, to be held in Munich, Germany, on November 25 and 26, 2014.

In October 2014, Genclis presented the first clinical data for Severidia ® at the Personalized Diagnostics Today session of the American Association for Clinical Chemistry (« AACC ») conference. These data were based on a robust retrospective study conducted on a sample of 52 patients from 10 different clinical centers and for which a genomic sequencing was performed through NGS technology. Twenty patients were used in a training set and 32 patients, with a similar profile, were used in blind replication. Data showed that Genclis' proprietary algorithms were able to predict individual patient cancer severity with greater than 90 % accuracy: i.e. 100% of patients classified in the "good outcome" subgroup (2/3 of patients in the replication set) were alive after 2,500 days.

Data presented in Munich include 15 additional TNBC patients and as well as a longer duration of the clinical observation (+ 9 month) for the first 32 patients in the initial replication set. The 15 additional patients came from the same NCI biobank, had same inclusion criteria and had DNA and RNA sequencing under the same protocol.

In the larger population of 47 patients, the probability of survival after 2,500 days for patients classified with a good outcome was unchanged, at 100%, and the p value of the statistical observation improved by a log (p < 10 -4 vs. p < 10 -5 ).

Dr. Bernard Bihain, CSO and Chairman of the Board of Genclis said: "These additional clinical data confirm the robustness of the test as a diagnostic tool for severity of triple-negative breast cancer". He added: "They warrant a rapid development of Severidia®. We are currently starting additional studies to confirm the clinical utility of the biomarker".

Stéphane Boissel, CEO of Genclis, said: " In 2015, we should obtain additional data that would give Severidia® a level of evidence compatible with expectations in terms of both registration and reimbursement of the test". He added: "In parallel, we will be conducting clinical validation studies in other indications so as to validate the cross-functional feature of this disruptive, proprietary approach in the growing field of cancer prognostic biomarker".

The AACC poster is available on the Company's website ( www.genclis.com ).

The presentation made in 4 th Munich Biomarker Conference will be posted on the Company's website from November 27, 2014.

About triple-negative breast cancer ("TNBC"):

Breast cancer has a global incidence of 1.677.000 new cases per year, including 794.000 new cases in developed countries (source: Globocan), of which 233.000 new cases in the USA and 367.000 new cases in the European Union. Breast cancer is qualified as "triple-negative" when estrogen, progesterone and HER2/Neu, the 3 main targets of modern breast cancer therapeutic agents, are not overexpressed in these cells.

This type of cancer account for 15 to 25% of all breast cancers (source: Medscape), or between 120.000 and 200.000 new cases per year in developed countries. It is considered as the most deadly breast cancer form, with more than 25% of deaths within 5 years of diagnostic. Chemotherapy is used in around 50% of TNBC cancer cases. TNBC tumors respond to chemotherapy. However, they are genetically unstable and thus resistance to chemotherapy treatment are developed in the first five years after chemotherapy. It is known that around 2/3 of TNBC are non-severe TNBC. However, without any proper tool to segment patients based on the severity of their cancer, most patients undergo chemotherapy.

It is commonly known that costs of care for TNBC are 80% above average breast cancer costs.

About Severidia ®:

Severidia ® is the first diagnostic product from the pioneering work on DNA/RNA transcription infidelity by Genclis. This work was patented (granted in the USA and Europe) and published (in PNAS) in 2007. Whereas DNA/RNA transcription is almost a match in normal cells, it has been shown to be divergent in cancer cells. And Genclis has demonstrated that the level of divergence correlates with clinical outcome of cancer patients.

By measuring precisely the divergence between DNA and RNA (the RNA/DNA Divergence Rate, or "RDD Rate"), Severidia ® could assess the risk of cancer relapse at a robustness level unseen in solid tumors as it does not prejudge of genes involved in the disease (a poorly documented information in solid tumors) but instead measures a biological phenomenon universally found in any given cancer.

This is why Genclis believes it could make of Severidia ® a scientific and technological gold standard of cancer prognostic biomarkers as the only test capable of classifying the "hard-to-classify" cancers.

About Genclis:

Genclis is a molecular diagnostic company in the fields of allergy and cancer. Started in 2004, the Company initiated the commercialization of its allergy molecular diagnostic tests in 2014.

In the field of cancer diagnostic, Genclis based its development on the concept of DNA/RNA divergences due to transcription infidelity, an original, proprietary disruptive science. This science has already led to encouraging results in the severity prognostic of triple negative breast cancer ("TNBC"), a severe form of breast cancer. Genclis intends to rapidly impose its solution, Severidia ©, as a standard for oncologists to offer their patients alternative treatment and monitoring options. 

Based in Nancy and Paris, Genclis had 40 employees as of October 1, 2014. Please visit: www.genclis.com .

Contacts:

Stéphane Boissel , CEO: +33.6.74.78.09.25 - sboissel@genclis.com

Bernard Bihain , Chairman and CSO: +33.6.33.02.90.88 - bbihain@genclis.com

ATCG Press:  Judith Aziza, +33.6.70.07.77.51 - presse@atcg-partners.com

PR Genclis result http://hugin.info/164309/R/1873825/660019.pdf

HUG#1873825

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cytonics Refines CYT-108 Trial Plan With Decade OA Data

Updated Category News Views 89

A Better Map Is Not a Working Drug Knee osteoarthritis has chewed up plenty of promising development plans because the disease moves at an aggravatingly uneven crawl. Cytonics has done something sensible before pushing deeper into CYT-108: it went back to long-term untreated patient data and asked which knees actually deteriorate fast enough for a trial to detect...

Continue Reading
Markel Elevates War Risk Expertise in London Market

Updated Category News Views 165

A Specialty Desk Gets Its Own Weather Vane War and political violence underwriting is not a corner of insurance where a fancy title change can be shrugged off. The ground shifts under the policyholder, the broker and the carrier without much warning, and a bad call can sit on a book for years. Markel Insurance has named Chloe Gordge Director of War and Political Violence...

Continue Reading
Nellie's 50% Booking Jump Reveals a Quieter Luxury

Updated Category News Views 134

Silicon Valley’s rich are apparently tired of performing wealth for strangers, and frankly, that tracks. Nellie’s 2027 forecast says its mostly tech-money clientele is moving past the old trophy case of private jets, famous resort towns, and suites priced like small houses. The prize now is privacy, a clean schedule, and somebody competent fixing the ugly little...

Continue Reading
TGHL Eyes U.S. Battery Shift Through EnChem Merger

Updated Category News Views 249

A Policy Squeeze Is Rewriting the Battery Map Battery supply chains are getting shoved through a narrower gate, and that is exactly why this proposed deal deserves a hard look. The GrowHub Limited wants to acquire EnChem America, a Georgia-based lithium-ion battery electrolyte producer, and the timing is plainly built around Washington's push to reduce reliance on...

Continue Reading
Sinopec’s Algerian Outreach Reveals a Patient Long Game

Updated Category News Views 109

Soft Power Does Not Run a Refinery, but It Matters A short video contest in Algiers will not move an oilfield schedule or settle a hydrocarbons negotiation. That is precisely why this Sinopec-backed event deserves a sober look rather than a chest-thumping one. On Nov. 15, Sinopec Group and the Chinese Embassy in Algeria co-hosted the final of their second youth cultural...

Continue Reading
Cold-Season Cleaning Advice Has a Practical Catch!

Updated Category News Views 53

Remote Controls Are Nobody’s First Suspect A television remote can make the rounds all evening and never see a cloth, which is precisely why Maid Brigade’s cold-and-flu-season reminder lands as common sense rather than revelation. The Scottsdale cleaning company is telling households to look past the usual kitchen counter and bathroom sink routine. Fair enough. People...

Continue Reading
BLLN Faces Fresh Questions After Short-Seller Report

Updated Category News Views 91

A six-percent air pocket is one thing; a disclosure mismatch is another beast entirely. BillionToOne shares fell on November 18 after short-seller Fuzzy Panda Research alleged the company had not disclosed meaningful regulatory scrutiny, including an alleged Tennessee matter in which regulators suspected fraud in 2024. That is an allegation from a short seller, not a...

Continue Reading
Veterans United Foundation Marks 15 Years of Giving

Updated Category News Views 62

A Milestone Measured in More Than Checks Fifteen years can turn a workplace charity into background noise, but this one plainly has not drifted into autopilot. Veterans United Foundation closed its 2026 anniversary campaign, called The Good Goes On, with $1.5 million directed to charitable organizations, 1,145 employee volunteers, and 2,680 hours of hands-on work. That is...

Continue Reading
APEC's Shared-Prosperity Message Needs More Detail

Updated Category News Views 50

Geese make handsome symbols, but markets cannot underwrite a metaphor. The Nov. 18, 2026 report from Xinhua News Agency looks back to remarks Chinese President Xi Jinping made 12 years ago, when he used swan geese to urge APEC economies toward greater cooperation and a new collective flight. Its present-day message is plainly hopeful: the APEC family is moving across the...

Continue Reading
HiTHIUM's 8-Hour Storage Pitch Faces Real Grid Tests

Updated Category News Views 89

Eight hours of stored electricity is where the sales brochure meets the ugly parts of the grid. HiTHIUM arrived at RE+ 2026 in Las Vegas, held November 17 through 19, with a broad storage pitch: systems ranging from two to eight hours, lithium-ion and sodium-ion chemistry, plus the software and validation work needed to make a battery plant behave when the local grid gets...

Continue Reading

Top 5 Most Recently Viewed Articles

Wind River Launches Innovative eLxr Pro for Modern Deployments

Updated Category News Views 314

Transforming Edge Computing with eLxr Pro Wind River, a leader in intelligent edge software solutions, has just launched a groundbreaking product, eLxr Pro. This is a commercial enterprise Linux distribution tailored to meet the rising demands of cloud-to-edge deployments, significantly improving performance and operational capabilities across a range of sectors. Meeting...

Continue Reading
VirnetX Welcomes Dr. Jamison as New Chief Technical Officer

Updated Category News Views 541

VirnetX Appoints a New Chief Technical Officer VirnetX Holding Corporation (NYSE: VHC) is excited to announce the appointment of Dr. John Anthony Jamison as their new Chief Technical Officer (CTO). His extensive background significantly bolsters the team’s expertise in secure communications technology. Dr. Jamison's Impressive Background Dr. Jamison brings a wealth of...

Continue Reading
NDEX Systems Enhances Advisor Workflows with New Technology

Updated Category News Views 188

Innovative Integration by NDEX Systems MONTREAL — NDEX Systems, a leader in multi-custodian data utility and wealth-management solutions, has recently unveiled a new integration that significantly enhances the advisor experience. This development introduces a sophisticated single sign-on (SSO) connection and a fully integrated client onboarding process with the Schwab...

Continue Reading
Transforming Agriculture: The Rise of Regenerative Practices

Updated Category News Views 239

The Rise of Regenerative Agriculture In the current agricultural landscape, regenerative agriculture has emerged as a crucial response to the pressing issues of climate change, soil degradation, and food security. This innovative farming method doesn't just optimize food production; it revitalizes ecosystems and offers economic advantages for farmers around the globe....

Continue Reading
Ericsson's Q2 2025 Performance Highlights and Future Strategies

Updated Category News Views 367

Financial Overview of Q2 2025 Ericsson has reported significant advancements in its financial performance for the second quarter of 2025. With operational excellence, the company has seen a remarkable 48% adjusted gross margin, marking a three-year high in adjusted EBITA margin. This reflects a strong commitment to strategic execution and operational improvements....

Continue Reading